The comment about “an aggressive launch” was obligatory and essentially vacuous, but the CEO also said Teva will continue to detail regular Copaxone even if they get FDA approval for the thrice-weekly product. This is new information.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.